Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Neurochem Res. 2012 Feb;37(2):370-80. doi: 10.1007/s11064-011-0620-1. Epub 2011 Oct 4.
Patients with glioblastoma multiforme (GBM) have poor therapeutic outcomes despite their current therapy. In an attempt to increase the efficacy of therapy for GBM, we studied the efficacy of arsenic trioxide (ATO), a newly introduced treatment for glioma, combined with silibinin, a natural polyphenolic flavonoid, in the GBM cell line, U87MG. The combination therapy synergically inhibited metabolic activity, cell proliferation, and gelatinase A and B activities; it also increased apoptosis. Additionally, it decreased the mRNA level of cathepsin B, uPA, matrix metalloproteinase-2 and 9, membrane type 1-MMP, survivin, BCL2, CA9; it increased mRNA level of caspase-3. Altogether, these results showed that ATO and silibinin in some cases improved and/or complemented the anticancer effects. This study may supply insight into the design of new combination cancer therapies to cells intrinsically less sensitive to routine therapies and suggested a new combination therapy for the highly invasive human glioma treatment.
尽管目前已有治疗方法，但多形性胶质母细胞瘤（GBM）患者的治疗效果仍不佳。为了提高 GBM 的治疗效果，我们研究了三氧化二砷（ATO）联合水飞蓟宾（一种新型治疗神经胶质瘤的天然多酚类黄酮）联合治疗 GBM 细胞系 U87MG 的疗效。联合治疗协同抑制代谢活性、细胞增殖以及明胶酶 A 和 B 的活性；还能增加细胞凋亡。此外，它还降低了组织蛋白酶 B、uPA、基质金属蛋白酶-2 和 9、膜型 1-MMP、survivin、BCL2、CA9 的 mRNA 水平；增加了 caspase-3 的 mRNA 水平。总之，这些结果表明，ATO 和水飞蓟宾在某些情况下改善和/或补充了抗癌作用。本研究可能为设计针对常规治疗方法敏感性较低的细胞的新型联合癌症治疗方法提供了思路，并为高度侵袭性人神经胶质瘤的治疗提供了一种新的联合治疗方法。
